Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236246 · ClinicalTrials.gov registry record · Phase 4
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
A Phase 4 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 206
- Enrollment target
NCT03236246: Completed Phase 4 study, sponsored by Keryx Biopharmaceuticals.
NCT03236246 is a Phase 4 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 206 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03236246, a Phase 4 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 206 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney disease (CKD).
Primary Outcome
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Estimates are from a mixed model of repeated measures (MMRM), including an intercept term and covariates for randomized treatment, visit, treatment by visit interaction, Baseline value, and Baseline value by visit interaction. The Kenward-Roger method was used along with an unstructured covariance matrix.
Interventions
- DRUG KRX-0502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 4 |
What the finished NCT03236246 record still lists
NCT03236246 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which KRX-0502 is the first listed.
NCT03236246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03236246 about?
NCT03236246 is a clinical study titled "KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)". The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney disease (CKD).
What is the current status of trial NCT03236246?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 206 participants. The study started on 2017-08-15. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT03236246?
The interventions under investigation include: KRX-0502 (DRUG).
Who is sponsoring clinical trial NCT03236246?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03236246's enrollment target sits among peer trials
206 401st of 2000 higher than 1,599 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI